Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 326 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: L-Serine Clear all
Not listed Early Phase 1 Interventional

Augmentation of Cognitive Training in Children With TBI With D-Cyloserine

NCT02312635
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
D-Cycloserine, Cogmed Working Memory Training
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

fMRI Study Examining Effects of D-cycloserine in Specific Phobia

NCT00591825
View directory record Official record
Conditions
Phobias
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III

NCT00784134
View directory record Official record
Conditions
Intraventricular Hemorrhage
Interventions
Alteplase, Normal saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 29, 2026, 2:45 PM EDT
Not listed Phase 1Phase 2 Interventional

Determining the Safety of L-serine in ALS

NCT01835782
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
L-Serine
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
2
States / cities
Phoenix, Arizona • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Not applicable Interventional Results available

Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory

NCT01449955
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

NCT01859026
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
MEK162, Erlotinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

NCT02066792
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia

NCT00742079
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Not applicable Interventional Results available

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers

NCT00633256
View directory record Official record
Conditions
Smoking
Interventions
Cycloserine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 29, 2026, 2:45 PM EDT
Withdrawn Phase 4 Interventional

Once Weekly D-cycloserine for Schizophrenia

NCT00964041
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 29, 2026, 2:45 PM EDT
Withdrawn Phase 2 Interventional

D-Serine for Cocaine Dependence Pilot

NCT01715051
View directory record Official record
Conditions
Cocaine Dependence
Interventions
D-serine, Cognitive Behavioral Therapy, Placebo
Drug · Behavioral
Lead sponsor
Theresa Winhusen
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 29, 2026, 2:45 PM EDT
Suspended Phase 1 Interventional

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122
View directory record Official record
Conditions
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions
Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents

NCT01157429
View directory record Official record
Conditions
Posttraumatic Stress Disorder, PTSD
Interventions
D-cycloserine, Placebo pill, CBT
Drug · Behavioral
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
13 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 29, 2026, 2:45 PM EDT
Active, not recruiting Phase 2 Interventional

Novel and Conventional Interventions for Cognitive and Emotional Flexibility in Patient Trauma

NCT07868627
View directory record Official record
Conditions
Depression, Anxiety, Trauma Patients
Interventions
D-Cycloserine (DCS), Transcranial Magnetic Stimulation, Unified Protocol, Psychoeducation
Drug · Device · Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

D-serine Augmentation of Neuroplasticity

NCT03711500
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
D-serine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 29, 2026, 2:45 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.

NCT02806414
View directory record Official record
Conditions
Rosacea
Interventions
Ivermectin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Not applicable Interventional Results available

Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo

NCT02582515
View directory record Official record
Conditions
Tourette Disorder, Chronic Tic Disorder
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 29, 2026, 2:45 PM EDT
Completed No phase listed Observational

Primary Hyperoxaluria Mutation Genotyping/Phenotyping

NCT02340689
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
Genetic Analysis
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Day and older
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 29, 2026, 2:45 PM EDT
Completed No phase listed Observational

Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer

NCT00965276
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

NCT02037555
View directory record Official record
Conditions
Cardiac Surgery, Cardiopulmonary Bypass
Interventions
AT-III (Human), Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
41
States / cities
Orange, California • San Francisco, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 29, 2026, 2:45 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Multi-Center, Open-Label Study

NCT01468259
View directory record Official record
Conditions
Renal Disease, End Stage Renal Disease
Interventions
Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 29, 2026, 2:45 PM EDT